Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TPMT | P51580 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12362308 | 0.83 | GPR35 (0.47) | GPR35MAPTKDM4ESMN1; SMN2VCAM1 | |
| SCHEMBL18189273 | 0.83 | GPR35 (0.47) | GPR35MAPTKDM4EMEN1KMT2A | |
| SCHEMBL12584687 | 0.77 | ALDH1A1 (0.47) | MAPTKDM4EMEN1HPGDCASP3 | |
| SCHEMBL11265430 | 0.77 | GPR35 (0.50) | GPR35MAPTKDM4EMEN1HPGD | |
| SCHEMBL15689571 | 0.76 | GPR35 (0.44) | GPR35MAPTSMN1; SMN2VCAM1PKM | |
| SCHEMBL523663 | 0.76 | AR (0.42) | KDM4EMEN1KMT2APOLBTDP1 | |
| SCHEMBL81383 | 0.76 | GPR35 (0.42) | GPR35MAPTKDM4EMEN1KMT2A | |
| SCHEMBL17090846 | 0.76 | TRPV1 (0.46) | GPR35MAPTKDM4EMEN1HPGD | |
| SCHEMBL17090848 | 0.76 | TRPV1 (0.46) | GPR35MAPTKDM4EMEN1HPGD | |
| SCHEMBL31029775 | 0.74 | PKM (0.60) | MAPTKDM4EMEN1HPGDCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724847-A | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2023-03-03 | — | — | CN | disclosed |
| CN-101631464-B | 2,3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives for the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-108774232-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-105254634-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives useful in the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11220513-B2 | Chromium-mediated coupling and application to the synthesis of halichondrins | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210009605-A1 | CHROMIUM-MEDIATED COUPLING AND APPLICATION TO THE SYNTHESIS OF HALICHONDRINS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-01-14 | — | — | US | disclosed |
| US-10633392-B2 | Chromium-mediated coupling and application to the synthesis of halichondrins | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200031843-A1 | CHROMIUM-MEDIATED COUPLING AND APPLICATION TO THE SYNTHESIS OF HALICHONDRINS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-01-30 | — | — | US | disclosed |
| US-10344038-B2 | Chromium-mediated coupling and application to the synthesis of halichondrins | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-07-09 | — | — | US | disclosed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | disclosed |
| EP-1549652-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220513-B2 | Chromium-mediated coupling and application to the synthesis of halichondrins | CROCC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KAT7 | GPR35 4126/4885MAPT 4866/4885KDM4E 3064/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | GPR35 717/4885MAPT 1939/4885KDM4E 3870/4885 |
| US-10344038-B2 | Chromium-mediated coupling and application to the synthesis of halichondrins | CA9, CROCC, CHD9 | GPR35 4323/4885MAPT 4877/4885KDM4E 3240/4885 |
| US-20210009605-A1 | CHROMIUM-MEDIATED COUPLING AND APPLICATION TO THE SYNTHESIS OF HALICHONDRINS | CROCC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KAT7 | GPR35 4126/4885MAPT 4866/4885KDM4E 3064/4885 |
| US-10633392-B2 | Chromium-mediated coupling and application to the synthesis of halichondrins | CA9, CROCC, CHD9 | GPR35 4323/4885MAPT 4877/4885KDM4E 3240/4885 |
| US-20200031843-A1 | CHROMIUM-MEDIATED COUPLING AND APPLICATION TO THE SYNTHESIS OF HALICHONDRINS | CROCC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KAT7 | GPR35 4126/4885MAPT 4866/4885KDM4E 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.